

SPECIALTY GUIDELINE MANAGEMENT

EPOGEN, PROCIT, RETACRIT (epoetin alfa)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Epoetin alfa is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.
2. Epoetin alfa is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in HIV-infected patients with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.
3. Epoetin alfa is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
4. Epoetin alfa is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. Epoetin alfa is not indicated for patients who are willing to donate autologous blood preoperatively.

B. Compendial Uses

1. Symptomatic anemia in patients with myelodysplastic syndromes (MDS)
2. Anemia in congestive heart failure
3. Anemia in rheumatoid arthritis
4. Anemia due to hepatitis C treatment with ribavirin in combination with either interferon alfa or peginterferon alfa
5. Anemia in patients whose religious beliefs forbid blood transfusions
6. Symptomatic anemia in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis
7. Cancer patients who are undergoing palliative treatment

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Note: Requirements regarding pretreatment hemoglobin level exclude values due to a recent transfusion. All members must be assessed for iron deficiency anemia and have adequate iron stores or are receiving iron therapy before starting Epogen/Procrit/Retacrit. Members may not use Epogen/Procrit/Retacrit concomitantly with other erythropoiesis stimulating agents.

A. Anemia Due to CKD

Epogen-Procrit-Retacrit 1619-A SGM P2018a

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Authorization of 12 weeks may be granted for members with pretreatment hemoglobin < 10 g/dL.

B. Anemia Due to Myelosuppressive Chemotherapy

Authorization of 12 weeks may be granted for members with nonmyeloid malignancy with pretreatment hemoglobin < 10 g/dL

C. Anemia in MDS

Authorization of 12 weeks may be granted for members with pretreatment hemoglobin < 10 g/dL whose pretreatment serum EPO level is < 500 mU/mL.

D. Reduction of Allogeneic Red Blood Cell Transfusion in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery

Authorization of 30 days may be granted for members scheduled to have an elective, noncardiac, nonvascular surgery when the pretreatment hemoglobin is $\leq$ 13 g/dL.

E. Anemia in Congestive Heart Failure (CHF)

Authorization of 12 weeks may be granted for members with pretreatment hemoglobin < 9 g/dL.

F. Anemia in Rheumatoid Arthritis (RA)

Authorization of 12 weeks may be granted for members with pretreatment hemoglobin < 10 g/dL.

G. Anemia Due to Hepatitis C Treatment

Authorization of 12 weeks may be granted for members with pretreatment hemoglobin < 10 g/dL who are receiving ribavirin in combination with either interferon alfa or peginterferon alfa.

H. Anemia Due to Zidovudine in HIV-infected Patients

Authorization of 12 weeks may be granted for members currently receiving zidovudine with pretreatment hemoglobin < 10 g/dL whose pretreatment serum EPO level is < 500 mU/mL.

I. Anemia in Members Whose Religious Beliefs Forbid Blood Transfusions

Authorization of 12 weeks may be granted for members with pretreatment hemoglobin < 10 g/dL.

J. Anemia in Primary Myelofibrosis (MF), Post-polycythemia Vera MF, and Post-Essential Thrombocythemia MF

Authorization of 12 weeks may be granted for members who meet ALL of the following criteria:

1. Pretreatment hemoglobin < 10 g/dL
2. Pretreatment serum erythropoietin level < 500 mU/mL

K. Anemia Due to Cancer

Authorization of 12 weeks may be granted for members who have cancer and are undergoing palliative treatment

III. CONTINUATION OF THERAPY

Note: Requirements regarding current hemoglobin level exclude values due to a recent transfusion. Members may not use Epogen/Procrit/Retacrit concomitantly with other erythropoiesis stimulating agents.

For all indications below: all members (including new members) requesting authorization for continuation of therapy after at least 12 weeks of ESA treatment must show a response with a rise in hemoglobin of $\geq$ 1 g/dL. Members who completed less than 12 weeks of ESA treatment and have not yet responded with a rise in

hemoglobin of ≥ 1 g/dL may be granted authorization of up to 12 weeks to allow for sufficient time to demonstrate a response.

A. Anemia Due to CKD

Authorization of 12 weeks may be granted for continuation of therapy when the current hemoglobin is ≤ 12 g/dL.

B. Anemia Due to Myelosuppressive Chemotherapy

Authorization of 12 weeks may be granted for the continuation of therapy in members with nonmyeloid malignancy with current hemoglobin is < 12 g/dL.

C. Anemia in MDS

Authorization of 12 weeks may be granted for continuation of treatment when the current hemoglobin is ≤ 12 g/dL

D. Anemia in CHF, RA

Authorization of 12 weeks may be granted for continuation of treatment when the current hemoglobin is ≤ 12 g/dL.

E. Anemia Due to Hepatitis C Treatment

Authorization of 12 weeks may be granted for continuation of treatment when the member meets ALL of the following criteria:

1. The member is receiving ribavirin in combination with either interferon alfa or peginterferon alfa
2. The current hemoglobin is ≤ 12 g/dL.

F. Anemia Due to Zidovudine in HIV-infected Patients

Authorization of 12 weeks may be granted for continuation of therapy in members receiving zidovudine when the current hemoglobin is ≤ 12 g/dL.

G. Anemia in Members Whose Religious Beliefs Forbid Blood Transfusions

Authorization of 12 weeks may be granted for continuation of treatment when the current hemoglobin is ≤ 12 g/dL.

H. Anemia in Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-Essential Thrombocythemia Myelofibrosis

Authorization of 12 weeks may be granted for continuation of treatment when the current hemoglobin is ≤ 12 g/dL.

I. Anemia Due to Cancer

Authorization of 12 weeks may be granted for members who have cancer and are undergoing palliative treatment

IV. REFERENCES

1. Epogen [package insert]. Thousand Oaks, CA: Amgen Inc.; July 2018.
2. Procrit [package insert]. Horsham, PA: Janssen Products.; July 2018.
3. Retacrit [package insert]. Lake Forest, IL: Hospira Inc.; May 2018
4. National Comprehensive Cancer Network. The NCCN Drugs & Biologics Compendium. <http://www.nccn.org>. Accessed September 19, 2018.
5. Micromedex Solutions [database online]. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed September 19, 2018.

Reference number(s)
1619-A

6. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed September 19, 2018.
7. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Int.* 2012;Suppl 2:279-335.
8. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. http://www2.kidney.org/professionals/KDOQI/guidelines_anemiaUP/. Accessed September 19, 2018.
9. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. *J Clin Oncol.* 2010;28(33):4996-5010.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer- and Chemotherapy-Induced Anemia. Version 3.2018. http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf. Accessed September 19, 2017.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 1.2019. http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed September 19, 2017.
12. Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians. Treatment of Anemia in Patients with Heart Disease: A Clinical Practice Guideline from the American College of Physicians. *Ann Intern Med.* 2013;159:770-779.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 1.2019. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed September 19, 2017.
14. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Erythropoietin treatment of the anemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. *Br J Haematol.* 2004;127(4):399-403.
15. Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, et al. Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials. *Ann Intern Med.*; 117:739–748. doi: 10.7326/0003-4819-117-9-739.
16. Gabrilove j, Paquette R, Lyons R, Mushtaq C, Sekeres M, Tomita D, Dreiling L. [Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes](#). *Br J Haematol.* 2008 Aug; 142(3): 379–393.